Sage Therapeutics (NASDAQ:SAGE) Earns Neutral Rating from Analysts at Robert W. Baird

Robert W. Baird assumed coverage on shares of Sage Therapeutics (NASDAQ:SAGE – Free Report) in a report issued on Wednesday morning, MarketBeat reports. The firm issued a neutral rating and a $15.00 price target on the biopharmaceutical company’s stock. Several other brokerages have also recently commented on SAGE. Truist Financial reduced their target price on […]

Related Keywords

Wellington , New Zealand General , New Zealand , Robertw Baird , , Vanguard Group Inc , Wellington Management Group , Sage Therapeutics Company Profile , Bellevue Group , Goldman Sachs Group , Sage Therapeutics Inc , Nasdaq , Sage Therapeutics , Free Report , Get Free Report , Management Group , Palo Alto Investors , Alto Investors , Sage Therapeutics Daily ,